Oxiconazole

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461375

CAS#: 64211-45-6

Description: Oxiconazole is an imidazole derivative and an antifungal medicine. It is used to treat certain kinds of fungal or yeast infections of the skin.


Chemical Structure

img
Oxiconazole
CAS# 64211-45-6

Theoretical Analysis

MedKoo Cat#: 461375
Name: Oxiconazole
CAS#: 64211-45-6
Chemical Formula: C18H13Cl4N3O
Exact Mass: 426.98
Molecular Weight: 429.120
Elemental Analysis: C, 50.38; H, 3.05; Cl, 33.04; N, 9.79; O, 3.73

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Oxiconazole; Oxiconazolum; Ro 13-8996; Ro-13-8996; Ro13-8996;

IUPAC/Chemical Name: (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethan-1-one O-(2,4-dichlorobenzyl) oxime

InChi Key: QRJJEGAJXVEBNE-HKOYGPOVSA-N

InChi Code: InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+

SMILES Code: ClC1=CC=C(/C(CN2C=CN=C2)=N/OCC3=CC=C(Cl)C=C3Cl)C(Cl)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 429.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: NIkitina VV, Zakharova NB, Gladilin GP, Korshunov GV. [The impact of concentrations of nitric oxide and activity of oxistat on development of inflammatory alterations in vascular wall]. Klin Lab Diagn. 2014 May;(5):11-3. Russian. PubMed PMID: 25338456.

2: Aydın E, Taştan E, Aydoǧan F, Karaca G, Asım Şafak M. Ototoxic effect of topical oxiconazole and terbinafine in rats. J Otolaryngol Head Neck Surg. 2012 Apr;41(2):78-83. PubMed PMID: 22569007.

3: Özdemir S, Tuncer Ü, Tarkan Ö, Akar F, Sürmelioğlu Ö. Effects of topical oxiconazole and boric acid in alcohol solutions to rat inner ears. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1023-7. doi: 10.1177/0194599813481565. Epub 2013 Mar 12. PubMed PMID: 23482479.

4: Kalis B, Grosshans E, Binet O, Garrel JB, Grossetête G, Jeanpierre G, Privat Y, Sonneck JM, Souteyrand P. [Oxiconazole cream versus ketoconazole cream. A prospective, randomized, double-blind, multicenter study in the treatment of inguinocrural dermatophytoses]. Ann Dermatol Venereol. 1996;123(8):447-52. French. PubMed PMID: 9033712.

5: Polak A. Oxiconazole, a new imidazole derivative. Evaluation of antifungal activity in vitro and in vivo. Arzneimittelforschung. 1982;32(1):17-24. PubMed PMID: 7037014.

6: Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. Clin Ther. 1991 Jan-Feb;13(1):126-41. Review. PubMed PMID: 2029718.

7: Verma A, Srivastava S, Sane SA, Marrapu VK, Srinivas N, Yadav M, Bhandari K, Gupta S. Antileishmanial activity of benzocycloalkyl azole oximino ethers: the conformationally constraint analogues of oxiconazole. Acta Trop. 2011 Feb;117(2):157-60. doi: 10.1016/j.actatropica.2010.10.011. Epub 2010 Nov 13. PubMed PMID: 21078278.

8: Shadomy S, Wang H, Shadomy HJ. Further in vitro studies with oxiconazole nitrate. Diagn Microbiol Infect Dis. 1988 Apr;9(4):231-7. PubMed PMID: 3180708.

9: Pariser DM, Pariser RJ. Oxiconazole nitrate lotion, 1 percent: an effective treatment for tinea pedis. Cutis. 1994 Jul;54(1):43-4. PubMed PMID: 7924451.

10: Schulman JA, Peyman GA, Dietlein J, Fiscella R. Toxicity of intravitreal oxiconazole. Int Ophthalmol. 1989 May;13(3):201-3. PubMed PMID: 2793313.

11: Wu SX, Shen YN, Yan N, Guo NR, Liu LL, Yang JQ. Experimental and clinical investigation on oxiconazole. Chin Med J (Engl). 1989 Aug;102(8):644-6. PubMed PMID: 2517622.

12: Milano J, Cardoso SG. Spectrophotometric determination of oxiconazole in topical lotion using methyl orange. J Pharm Biomed Anal. 2005 Apr 1;37(4):639-42. Epub 2004 Dec 21. PubMed PMID: 15797782.

13: Wagner W, Reckers-Czaschka R. [Oxiconazole in dermatomycosis--a double-blind, randomized therapy compared with bifonazole]. Mykosen. 1987 Oct;30(10):484-92. German. PubMed PMID: 3325843.

14: Polak-Wyss A, Lengsfeld H, Oesterhelt G. Effect of oxiconazole and Ro 14-4767/002 on sterol pattern in Candida albicans. Sabouraudia. 1985 Dec;23(6):433-41. PubMed PMID: 3913013.

15: Gouveia DC, Jones da Silva C. Oxiconazole in the treatment of vaginal candidiasis: single dose versus 3-day treatment with econazole. Pharmatherapeutica. 1984;3(10):682-5. PubMed PMID: 6463068.

16: Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica. 1987;175(6):293-5. PubMed PMID: 3319722.

17: Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol. 1996 Aug;35(8):591-3. PubMed PMID: 8854165.

18: Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984;30(4):244-7. PubMed PMID: 6086246.

19: Singh SM, Sharma S, Chatterjee PK. Clinical and experimental mycotic keratitis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in the animal model. Mycopathologia. 1990 Dec;112(3):127-37. PubMed PMID: 2089254.

20: Milano J, Morsch LM, Cardoso SG. LC method for the analysis of Oxiconazole in pharmaceutical formulations. J Pharm Biomed Anal. 2002 Sep 5;30(2):175-80. PubMed PMID: 12191701.